Measles vaccination timeliness by age 10 and coverage by age 12 months in intervention arms compared with the control arm
| N | No vaccinated (%) | RR (95% CI) | Adjusted RR (95% CI)* | P value | RD (95% CI) | Adjusted RD (95% CI)* | P value | |
| MCV1 at 10 months | ||||||||
| Intention-to-treat analysis | ||||||||
| Control | 160 | 109 (68) | Ref | Ref | – | Ref | Ref | – |
| SMS | 146 | 114 (78) | 1.15 (1.01 to 1.32) | 1.13 (0.99 to 1.30) | 0.070 | 10.0 (0.1 to 19.8) | 9.2 (−0.6 to 19.0) | 0.066 |
| SMS +150KES | 149 | 116 (78) | 1.14 (1.00 to 1.31) | 1.16 (1.01 to 1.32) | 0.035 | 9.7 (−0.1 to 19.5) | 10.6 (0.8 to 20.3) | 0.034 |
| Per-protocol analysis | ||||||||
| Control | 160 | 109 (68) | Ref | Ref | – | Ref | Ref | – |
| SMS | 126 | 100 (79) | 1.16 (1.01 to 1.34) | 1.15 (1.00 to 1.32) | 0.052 | 11.2 (1.1 to 21.3) | 10.2 (0.1 to 20.3) | 0.048 |
| SMS +150KES | 126 | 99 (79) | 1.15 (1.00 to 1.33) | 1.17 (1.02 to 1.35) | 0.024 | 10.4 (0.3 to 20.6) | 11.6 (1.4 to 21.7) | 0.025 |
| MCV1 at 12 months | ||||||||
| Intention-to-treat analysis | ||||||||
| Control | 160 | 125 (78) | Ref | Ref | – | Ref | Ref | – |
| SMS | 146 | 123 (84) | 1.08 (0.97 to 1.20) | 1.07 (0.96 to 1.19) | 0.199 | 6.1 (−2.6 to 14.8) | 5.7 (−3.0 to 14.3) | 0.199 |
| SMS + 150KES | 149 | 126 (85) | 1.08 (0.97 to 1.20) | 1.09 (0.97 to 1.20) | 0.156 | 6.4 (−2.2 to 15.1) | 6.8 (−1.8 to 15.3) | 0.119 |
| Per-protocol analysis | ||||||||
| Control | 160 | 125 (78) | Ref | Ref | – | Ref | Ref | – |
| SMS | 126 | 107 (85) | 1.09 (0.97 to1.21) | 1.08 (0.97 to1.20) | 0.163 | 6.8 (−2.2 to 15.7) | 6.3 (−2.6 to 15.2) | 0.165 |
| SMS + 150KES | 126 | 106 (84) | 1.08 (0.96 to1.20) | 1.08 (0.97 to1.21) | 0.166 | 6.0 (−0.3 to 15.0) | 6.4 (−2.5 to 15.3) | 0.161 |
Bold indicates p<0.05.
*RR and RD adjusted for maternal age.
RR, relative risk; RD, risk difference; MCV1, measles-containing vaccine; SMS, short message service; KES, Kenya Shillings; Ref, reference group.